Your fact-checks will appear here
Commune in Val-d'Oise, France
Ultrasensitive PSA (uPSA) assays detect PSA at levels below 0.1 ng/mL — in some labs down to ~0.001–0.006 ng/mL — and so can identify biochemical recurrence earlier than standard assays, which typical...
Three major prostate‑cancer guideline bodies—NCCN, AUA, and EAU—agree on the central role of serial PSA after radical prostatectomy but diverge on measurement sensitivity, timing of intervention, imag...
Age-related penile shrinkage (penile atrophy) has multiple causes and is sometimes reversible: treatments exist that can slow, partly reverse, or compensate for loss of length depending on the cause, ...
There is no single universally agreed PSA cut‑off after radical prostatectomy that defines biochemical recurrence; many expert groups and major centres use two consecutive values ≥0.2 ng/mL as the pra...
PSA doubling time (PSADT) is usually calculated from serial PSA measurements by fitting an exponential growth model — commonly by taking the natural log of PSA values, deriving a slope by linear regre...
Three categories of randomized trials are actively testing whether PSMA PET–guided changes to salvage radiotherapy improve outcomes: a completed/phase‑II randomized study reported in meetings with a f...
Surgeons and urologists converge on a small set of reproducible techniques—most commonly bone‑pressed erect length (BPEL) and stretched penile length (SPL)—measured with a rigid ruler pressed to the p...
Major urology societies (EAU, AUA, CUA) publish rigorous clinical-guideline frameworks and endorse high standards for study design, reporting and quality, but the publicly available guideline portfoli...
Biochemical recurrence that is suspected or imaged without a concomitant rise in standard PSA levels is unusual but documented, and management balances early salvage intent against risks of overtreatm...
Biochemical recurrence (BCR) is a rising PSA after definitive local therapy and occurs in roughly 20–50% of men within 10 years; management is risk‑stratified and ranges from observation to salvage ra...
After radical prostatectomy, biochemical recurrence (BCR) is commonly defined as a rising PSA with thresholds historically at ≥0.2 ng/mL (post‑prostatectomy) but contemporary practice uses ultrasensit...
Standard guidelines converge on regular PSA surveillance after radical prostatectomy, typically more frequent in the early years and annual thereafter; most recommendations call for testing every 3–6 ...